Loose Christopher R.
Known title: Chief Scientific OfficerCIK: 0001785299
Associated companies
Transaction History
| KRRO | ▼ Sell | Open Market | 1,344 | $618 | 7/28/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,373 | $728 | 7/27/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,329 | $678 | 7/26/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,390 | $695 | 7/25/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,438 | $777 | 7/24/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,333 | $813 | 7/21/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,361 | $871 | 7/20/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,335 | $868 | 7/19/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,484 | $831 | 7/18/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,415 | $948 | 7/17/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 906 | $535 | 7/14/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,329 | $518 | 7/13/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,335 | $521 | 7/12/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,363 | $504 | 7/11/2023 | View on chart |
| KRRO | ▲ Buy | Option Exercise | 4,546 | — | 7/10/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,304 | $482 | 7/10/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,306 | $470 | 7/7/2023 | View on chart |
| KRRO | ▲ Buy | Option Exercise | 4,546 | — | 7/7/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,384 | $471 | 7/6/2023 | View on chart |
| KRRO | ▲ Buy | Option Exercise | 4,546 | — | 7/6/2023 | View on chart |
| KRRO | ▲ Buy | Option Exercise | 4,546 | — | 7/5/2023 | View on chart |
| KRRO | ▼ Sell | Open Market | 4,415 | $7K | 7/6/2022 | View on chart |
| KRRO | ▲ Buy | Option Exercise | 15,000 | — | 7/5/2022 | View on chart |
| KRRO | ▼ Sell | Open Market | 1,069 | $4K | 2/22/2022 | View on chart |
| KRRO | ▼ Sell | Open Market | 974 | $4K | 2/18/2022 | View on chart |
| KRRO | ▼ Sell | Open Market | 900 | $4K | 2/17/2022 | View on chart |
| KRRO | ▼ Sell | Open Market | 851 | $4K | 2/16/2022 | View on chart |
| KRRO | ▼ Sell | Open Market | 863 | $4K | 2/15/2022 | View on chart |
| KRRO | ▲ Buy | Option Exercise | 15,000 | — | 2/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Korro Bio Begins Phase 1/2 Trial for KRRO-121
Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.
Korro Bio Begins Phase 1/2 Trial for KRRO-121. Korrr Bio has begun dosing the first cohort of its Phase 1/2 study for KRRO-121, a therapy aimed at treating hyperammonemia in patients with urea cycle disorders. The initiation of this trial marks a significant milestone in the drug’s development timeline. Analysts continue to hold a $15 price target, reflecting confidence in the program. Current technical data shows the stock trading near its 52‑week low with an RSI of 39.7.